Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, Lothar Müller, Thomas J Ettrich, Petra Buechner-Steudel, Michael Geißler, Jörg Trojan, Nicolas Moosmann, Gunnar Folprecht, Johannes Schmidt, Stephan Kanzler, Frank Kullmann, Jean-Charles Moulin, Jens Werner, Martin K Angele, Victoria Probst, Swantje Held, Christoph Schulz, Myrto Boukovala
INTRODUCTION: S-1 has been shown to be an effective adjuvant treatment option for East Asian patients who underwent gastrectomy for stage II/III gastric cancer. We conducted a phase I/II study to evaluate the feasibility, tolerability and efficacy of administering S-1 in the adjuvant setting after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (EGJ) in Caucasian patients. METHODS: In this single-cohort, open-label, phase I/II trial, we enrolled patients with locally advanced adenocarcinoma of the stomach or EGJ having undergone R0-resection with or without neoadjuvant treatment...
April 2, 2024: Oncology Research and Treatment